Electrical Geodesics, Inc. Release: AGM Results
EUGENE, OREGON, US, 17 June 2014 – Electrical Geodesics, Inc. (“EGI” or the “Company”), a leading neurodiagnostic medical technology company, today announces that all of the resolutions set out in the Company’s Notice of Annual General Meeting (the “Meeting”) issued to stockholders on 16 May 2014 were passed by stockholders at the Meeting held in Eugene at 9.30 PST yesterday. The Annual Report and Accounts for the year ended 31 December 2013 were also received by the meeting.
Don Tucker, CEO of EGI, addressed the meeting briefly, summarising the information on the progress of EGI within the Annual Report and various press releases issued by the Company.
He added: “We will provide detailed comment on current trading with our interim results in early September, however we are happy to see some revival of the grant funding that is so vital to our research customers, as well as the increasing level of interest in and satisfaction with our new hardware and software platform. As announced recently, we believe that therapeutic intervention through neuromodulation is an area of great potential for EGI. Our GTEN product was showcased at a major research meeting, OHBM, in Hamburg last week and the level of interest this received was encouraging. We are also delighted to partner with Soterix Medical and will be marketing their tDCS products. Bringing these two technologies to our customers will put EGI at the front of this exciting new field of neuromodulation.” Proxy Voting Results
Proxy and actual voting results in respect of Ordinary Resolutions 1 to 3 are shown below.
|
RESOL-UTION |
PROXY VOTES FOR |
VOTES PRESENT FOR |
TOTAL VOTES FOR |
% |
VOTES AGAINST
|
% |
VOTES WITHHELD |
% |
|
1.1 |
4,944,877 |
16,907,122 |
21,851,999 |
89.38% |
1,499,999 |
6.14% |
0 |
0% |
|
1.2 |
4,944,877 |
16,907,122 |
21,851,999 |
89.38% |
1,499,999 |
6.14% |
0 |
0% |
|
1.3 |
4,944,877 |
16,907,122 |
21,851,999 |
89.38% |
1,499,999 |
6.14% |
0 |
0% |
|
1.4 |
4,944,877 |
16,907,122 |
21,851,999 |
89.38% |
1,499,999 |
6.14% |
0 |
0% |
|
1.5 |
4,944,877 |
16,907,122 |
21,851,999 |
89.38% |
1,499,999 |
6.14% |
0 |
0% |
|
2 |
4,111,544 |
16,907,122 |
21,018,666 |
85.97% |
2,333,332 |
9.54% |
0 |
0% |
|
3 |
4,944,877 |
16,907,122 |
21,851,999 |
89.38% |
1,499,999 |
6.14% |
0 |
0% |
Ordinary Resolutions
1.1 To reappoint Don Tucker as a director
1.2 To reappoint Ann Bunnenberg as a director
1.3 To reappoint Christine Soden as a director
1.4 To reappoint John Brown as a director
1.5 To reappoint Raymond Englander as a director
2. To re-appoint Baker Tilly UK Audit LLP as auditors of the Company.
3. To authorise the Directors of the Company to determine the remuneration of the auditors.
Copies of all resolutions and all documents referred to above are available on the Company's website at www.egi.com.
For more information contact:
|
EGI |
|
|
UK: Christine Soden, CFO |
+44 7710 484199 |
|
US: Ann Bunnenberg |
+1 541 687 7962 |
|
|
|
|
|
|
|
|
|
|
Peel Hunt LLP (NOMAD and Broker) |
+44 (0) 20 7418 8900 |
|
James Steel, Clare Terlouw
|
|
|
FTI Consulting (PR Advisors) |
+44 (0) 20 3727 1000 |
|
Simon Conway, Mo Noonan |
|
About EGI
Founded in 1992, EGI designs, develops and commercialises a range of non-invasive neurodiagnostic products used to monitor and interpret brain activity based on its proprietary dense array electroencephalography ("dEEG") platform technology. The Company’s technology uses up to 256 sensors, providing much higher resolution brain activity data compared to conventional 8 or 16 channel EEG and is used in medical, clinical and research settings in a diverse range of applications including important areas such as the diagnosis and monitoring of epilepsy, neurosurgical planning, sleep assessment, and many others.
EGI’s dense array technology capitalizes on the Company’s unique Hydrocel Geodesic Sensor Net which allows faster, easier, and more convenient placement of many EEG sensors in an even distribution over the entire scalp, providing more accurate and precise diagnosis and measurement. EGI’s technology is now widely used in neuroscience research laboratories and is becoming more commonly used in clinics, care centers, and hospitals around the world. Data is measured and visualised using EGI’s proprietary amplifier technology and software, providing a complete, advanced, high-resolution EEG platform. The Company’s products are compatible with multiple diagnostic and imaging technologies, including magnetic resonance (MR) imaging, functional MRI (fMRI), and magneto-encephalography (MEG).
In April 2013 EGI commenced trading on the London Stock Exchange AIM market under the symbol EGI.L. See www.egi.com for more information on the Company.
Help employers find you! Check out all the jobs and post your resume.